Today’s Stock Alert: It Seems Endo International plc – Ordinary Shares Will Go Down. Have Another Big Decline

Today's Stock Alert: It Seems Endo International plc   Ordinary Shares Will Go Down. Have Another Big Decline

The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) is a huge mover today! About 4.06M shares traded hands. Endo International plc – Ordinary Shares (NASDAQ:ENDP) has declined 51.04% since March 9, 2016 and is downtrending. It has underperformed by 58.45% the S&P500.
The move comes after 7 months negative chart setup for the $4.56 billion company. It was reported on Oct, 12 by Barchart.com. We have $17.80 PT which if reached, will make NASDAQ:ENDP worth $410.40 million less.

Analysts await Endo International plc – Ordinary Shares (NASDAQ:ENDP) to report earnings on November, 3. They expect $0.84 EPS, down 17.65% or $0.18 from last year’s $1.02 per share. ENDP’s profit will be $195.83M for 5.82 P/E if the $0.84 EPS becomes a reality. After $0.86 actual EPS reported by Endo International plc – Ordinary Shares for the previous quarter, Wall Street now forecasts -2.33% negative EPS growth.

Endo International plc – Ordinary Shares (NASDAQ:ENDP) Ratings Coverage

Out of 16 analysts covering Endo International plc (NASDAQ:ENDP), 9 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 56% are positive. Endo International plc has been the topic of 35 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The company was upgraded on Friday, November 13 by Standpoint Research. The firm has “Outperform” rating by Northland Capital given on Thursday, September 29. The firm has “Neutral” rating given on Monday, June 6 by Goldman Sachs. The firm earned “Buy” rating on Friday, November 6 by Deutsche Bank. BMO Capital Markets initiated Endo International plc – Ordinary Shares (NASDAQ:ENDP) on Wednesday, June 29 with “Market Perform” rating. The firm has “Sector Perform” rating by RBC Capital Markets given on Friday, May 6. Mizuho downgraded the stock to “Neutral” rating in Monday, November 16 report. The company was initiated on Thursday, April 21 by JMP Securities. The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) has “Neutral” rating given on Monday, June 13 by Mizuho. The rating was initiated by Nomura on Tuesday, September 29 with “Buy”.

According to Zacks Investment Research, “Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.”

Insitutional Activity: The institutional sentiment increased to 0.95 in Q2 2016. Its up 0.03, from 0.92 in 2016Q1. The ratio increased, as 76 funds sold all Endo International plc – Ordinary Shares shares owned while 90 reduced positions. 42 funds bought stakes while 115 increased positions. They now own 192.40 million shares or 1.49% more from 189.57 million shares in 2016Q1.
Babson Mngmt Ltd Company has invested 0.02% of its portfolio in Endo International plc – Ordinary Shares (NASDAQ:ENDP). Commonwealth Comml Bank Of has 1,467 shares for 0% of their US portfolio. Proshare Limited Liability Co reported 254,473 shares or 0.05% of all its holdings. Raymond James Financial Svcs Advsrs has invested 0% of its portfolio in Endo International plc – Ordinary Shares (NASDAQ:ENDP). Aqr last reported 4.65 million shares in the company. Utah Retirement holds 0.02% of its portfolio in Endo International plc – Ordinary Shares (NASDAQ:ENDP) for 37,221 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 24,277 shares for 0% of their US portfolio. The Australia-based Amp Invsts Limited has invested 0.03% in Endo International plc – Ordinary Shares (NASDAQ:ENDP). Tcw Grp Inc Inc has 35,462 shares for 0% of their US portfolio. Qs Investors holds 0% or 2,630 shares in its portfolio. Blackrock Advsr Ltd Liability holds 0% of its portfolio in Endo International plc – Ordinary Shares (NASDAQ:ENDP) for 233,028 shares. Blackrock last reported 417,317 shares in the company. First Limited Partnership holds 0.03% of its portfolio in Endo International plc – Ordinary Shares (NASDAQ:ENDP) for 517,586 shares. Ubs Asset Management Americas last reported 0.01% of its portfolio in the stock. Parallax Volatility Advisers Limited Partnership reported 23,486 shares or 0% of all its holdings.

More recent Endo International plc – Ordinary Shares (NASDAQ:ENDP) news were published by: Valuewalk.com which released: “Endo International plc – Ordinary Shares (ENDP) Collapses Taking Hedge Fund …” on May 06, 2016. Also Valuewalk.com published the news titled: “Endo International plc – Ordinary Shares (ENDP) Shares Soar” on August 09, 2016. Investorplace.com‘s news article titled: “Why Salesforce.com, Inc. (CRM), Endo International plc – Ordinary Shares (ENDP …” with publication date: August 15, 2016 was also an interesting one.

ENDP Company Profile

Endo International plc, incorporated on October 31, 2013, is a global specialty pharmaceutical firm focused on developing, manufacturing, marketing and distributing branded and generic pharmaceutical products, as well as over-the-counter medications through its operating companies- Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs and SOMAR. The Company’s divisions include U.S. Branded Pharmaceuticals, which offer portfolio of branded pharmaceuticals such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, BELBUCA, Fortesta Gel, Testim, Aveed, Supprelin LA, and XIAFLEX; U.S. Generic Pharmaceuticals portfolio consists of tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches, and International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American, South African and world markets. It sells generic products primarily in the United States across multiple therapeutic categories.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: ,

Leave a Comment